Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18902033 | 0.81 | EPHX1 (0.34) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL6276759 | 0.78 | EPHX1 (0.36) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL8260381 | 0.77 | — | — | |
| SCHEMBL13611895 | 0.76 | L3MBTL1 (0.36) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL25564484 | 0.73 | MEN1 (0.40) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL20953659 | 0.73 | MEN1 (0.40) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL153717 | 0.73 | L3MBTL1 (0.42) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL24943572 | 0.72 | PKM (0.36) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL18016462 | 0.71 | ALDH1A1 (0.42) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL8369697 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | EPHX1 612/4885MEN1 310/4885KMT2A 97/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | EPHX1 443/4885MEN1 330/4885KMT2A 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.